Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARLA-M19 CD19 CAR-T in relapsed/refractory CD19-positive AML
2023-509212-29-01Phase 2Authorised
- Sponsor
- CHU de Lille
- Start
- Jul 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zorpocabtagene autoleucel in acute myeloid leukemia (AML), sponsored by CHU de Lille. Primary endpoint: Non-progression mortality at 1 month. Planned start Jul 2025; status: authorised.
02
Drugs
zorpocabtagene autoleucel
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2023-509212-29-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509212-29-01.